Skip to main content

Sagimet Biosciences, Inc. (SGMT)

Sagimet Biosciences will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Market Capn/a
Revenue (ttm)n/a
Net Income (ttm)-11.37M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About SGMT

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of several diseases that result from the overproduction of the fatty acid, palmitate. Based on our clinical and preclinical data, we believe that our wholly-owned pipeline of oral FASN inhibitors has the potential to offer treatments for indications in several therapeutic areas of high unmet medical need including liver diseases and cancers. TVB-2640, whic...

IndustryPharmaceutical Preparations
IPO DatePending
CEOGeorge Kemble, Ph.D.
Employees5
Stock ExchangeNASDAQ
Ticker SymbolSGMT
Full Company Profile

Financial Performance

Financial Statements

News

Sagimet Biosciences IPO Registration Document (S-1)

Sagimet Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC